AMRX
Amneal Pharmaceuticals, Inc.NASDAQHealthcare$12.48-1.04%ClosedMarket Cap: $3.93B
As of 2026-04-06
Valuation
P/E (TTM)
54.49
PEG
0.34
P/B
-54.67
P/S
1.29
EV/EBITDA
10.45
DCF Value
$17.41
FCF Yield
6.1%
Div Yield
0.0%
Margins & Returns
Gross Margin
36.9%
Operating Margin
10.8%
Net Margin
2.4%
ROE
-67.9%
ROA
2.0%
ROIC
10.6%
Income Statement
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q4 2025 | $814.3M | 36.5% | $114.5M | $35.1M | $0.11 | — |
| FY 2025 | $3.02B | 37.6% | $423.1M | $72.1M | $0.22 | — |
| Q3 2025 | $784.5M | 34.9% | $-117.0K | $2.4M | $0.01 | — |
| Q2 2025 | $724.5M | 39.5% | $111.4M | $22.4M | $0.07 | — |
| Q1 2025 | $695.4M | 36.8% | $100.3M | $12.2M | $0.04 | — |
| Q4 2024 | $730.5M | 36.0% | $75.8M | $-31.1M | $-0.10 | — |
| FY 2024 | $2.79B | 36.5% | $249.3M | $-116.9M | $-0.38 | — |
| Q3 2024 | $702.5M | 38.4% | $88.8M | $-156.0K | $-0.00 | — |
| Q2 2024 | $701.8M | 35.6% | $95.5M | $6.0M | $0.02 | — |
| Q1 2024 | $659.2M | 36.1% | $-10.7M | $-91.6M | $-0.30 | — |
| Q4 2023 | $617.0M | 36.5% | $14.2M | $-98.6M | $-0.40 | — |
| FY 2023 | $2.39B | 36.1% | $204.4M | $-84.0M | $-0.48 | — |